AU2001283295A1 - Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists - Google Patents

Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists

Info

Publication number
AU2001283295A1
AU2001283295A1 AU2001283295A AU8329501A AU2001283295A1 AU 2001283295 A1 AU2001283295 A1 AU 2001283295A1 AU 2001283295 A AU2001283295 A AU 2001283295A AU 8329501 A AU8329501 A AU 8329501A AU 2001283295 A1 AU2001283295 A1 AU 2001283295A1
Authority
AU
Australia
Prior art keywords
emmprin
cyp
leu
protein
emmprtn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283295A
Other languages
English (en)
Inventor
Michael I Bukrinsky
Barbara A Sherry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokine Pharmasciences Inc
Original Assignee
PICOWER INST MED RES
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PICOWER INST MED RES, Picower Institute for Medical Research filed Critical PICOWER INST MED RES
Publication of AU2001283295A1 publication Critical patent/AU2001283295A1/en
Assigned to CYTOKINE PHARMASCIENCES, INC reassignment CYTOKINE PHARMASCIENCES, INC Request for Assignment Assignors: THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001283295A 2000-08-10 2001-08-10 Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists Abandoned AU2001283295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63703300A 2000-08-10 2000-08-10
US09/637,033 2000-08-10
PCT/US2001/025178 WO2002013763A2 (fr) 2000-08-10 2001-08-10 Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline

Publications (1)

Publication Number Publication Date
AU2001283295A1 true AU2001283295A1 (en) 2002-02-25

Family

ID=24554263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283295A Abandoned AU2001283295A1 (en) 2000-08-10 2001-08-10 Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists

Country Status (6)

Country Link
EP (1) EP1309346A4 (fr)
JP (1) JP2004505997A (fr)
AU (1) AU2001283295A1 (fr)
CA (1) CA2418303A1 (fr)
IL (1) IL154358A0 (fr)
WO (1) WO2002013763A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1442203A (zh) * 2003-05-15 2003-09-17 陈志南 Sars冠状病毒和aids病毒（hiv－1）－cd147受体靶位拮抗剂
WO2005092381A1 (fr) * 2004-03-25 2005-10-06 Centocor, Inc. Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
JP5080252B2 (ja) * 2004-07-23 2012-11-21 ジーイー・ヘルスケア・ユーケイ・リミテッド 細胞周期を知らせる細胞系
JP4911950B2 (ja) * 2005-11-07 2012-04-04 晃 伊東 Ｍｍｐ−１の部分ペプチドを用いた癌浸潤・転移阻害薬
US8007808B2 (en) 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
US20110287008A1 (en) * 2008-05-23 2011-11-24 Uti Limited Partnership Inhibition of emmprin to treat multiple sclerosis
US8338171B2 (en) * 2009-08-31 2012-12-25 Centocor Ortho Biotech Inc. Baboon homolog of human CD147
JP2015524418A (ja) * 2012-07-27 2015-08-24 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７
WO2016054354A1 (fr) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour le traitement de tumeurs malignes
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN117187190A (zh) * 2023-11-07 2023-12-08 深圳湾实验室 抗亲环素a单抗及其在类风湿性关节炎治疗中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
KR20010034554A (ko) * 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 ｃｄ147 결합 분자

Also Published As

Publication number Publication date
IL154358A0 (en) 2003-09-17
WO2002013763A3 (fr) 2002-08-15
EP1309346A2 (fr) 2003-05-14
EP1309346A4 (fr) 2005-06-01
JP2004505997A (ja) 2004-02-26
WO2002013763A2 (fr) 2002-02-21
CA2418303A1 (fr) 2002-02-21

Similar Documents

Publication Publication Date Title
Tanaka et al. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.
Dong et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation.
Hooper et al. Membrane protein secretases
US7063971B2 (en) Phosphodiesterase enzymes
JP2000023682A (ja) ホスホジエステラ―ゼ酵素
JP2001501444A (ja) Ｏｂ受容体ならびに体重障害の診断および治療の方法
US20030229203A1 (en) Chemokine variants and methods of use
KR100536394B1 (ko) Fas/ap01수용체들의기능조절인자
JP4240537B2 (ja) Ｇ―ベータ―ガンマ調節ホスファチジルイノシトール―３’キナーゼ
AU2001283295A1 (en) Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists
US5721104A (en) Screening assay for anti-HIV drugs
AU719816B2 (en) Phospholipase C homolog
US20030185828A1 (en) Novel aggrecanase
CA2223038A1 (fr) Recepteur du genre c5a a sept transmembranes
WO1998020126A1 (fr) Sequences nucleotidiques codant des proteines associees de phosphatidylinositol-3 kinase et leurs utilisations
US7060810B2 (en) Regulation of human eosinophil serine protease 1-like enzyme
Miller et al. Phosphorylation and degradation of HMG CoA reductase
US20060211037A1 (en) Novel mouse CXC chemokine receptor
CA2217010A1 (fr) Nouvel homologue de cathepsine c
US6613506B1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6187909B1 (en) Viral encoded semaphorin protein receptor polypeptides
WO2004061088A2 (fr) Compositions et methodes d'inhibition d'une infection par le virus de l'immunodeficience humaine par regulation vers l'aval de genes cellulaires humains
CA2121302A1 (fr) Recepteur viral amphotrope
WO2004053094A2 (fr) Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains
US20030095968A1 (en) Viral encoded semaphorin protein receptor DNA and polypeptides

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application